SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to Michael Burry's disclosure of a long-term position and recent insider share purchases by CEO Ryan Cohen and other directors, which has driven substantial trading volume. The community is actively discussing whether this signifies a fundamental value play or a potential for renewed meme stock volatility, with many anticipating further catalysts.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending following a proposed near-flat Medicare Advantage rate increase for 2027 from the Trump Administration, significantly lower than Wall Street anticipated. This pre-earnings announcement has sparked a sector-wide sell-off and heated community debate, with many fearing future margin pressure while others see it as an overreaction and a compelling buying opportunity. Investors are sharply divided on whether this signals a lasting challenge or a temporary market dislocation.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines ($LUNR) is trending following its selection by NASA as the sole private company to track the high-profile Artemis II lunar mission, leveraging its Space Data Network. The community views this as a significant validation of LUNR's capabilities, bolstering its position as a key partner for NASA and a front-runner for future substantial contracts like the highly anticipated Lunar Terrain Vehicle (LTV) award.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom is capturing market attention as its strategic investment in AI company Anthropic is being re-evaluated, with analysts now estimating its worth significantly higher than the initial stake. This perceived 'hidden gem,' alongside a strong earnings report and raised guidance, is driving a significant breakout, with many in the community now discussing Zoom as a 'comeback kid' leveraging its substantial cash reserves and AI integration.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is experiencing massive upward momentum, driven by its low float and ongoing speculation around its AI business, with community discussions linking it to the "TrumpRx" initiative for pharmaceutical advertising. This has ignited a fierce battle between aggressive bulls anticipating a significant short squeeze and bears warning of an extended, overbought market ripe for rapid profit-taking, creating a highly volatile trading environment.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is actively trending following its significant acquisition of a chipmaker, aiming to become a vertically integrated leader in quantum computing. The community is sharply divided, debating potential shareholder dilution and immediate market pressure against the strategic long-term benefits of securing a domestic supply chain and accelerating its hardware roadmap. This bold move is widely viewed as a pivotal step in the ongoing global quantum computing race.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is gaining significant traction as an AI-powered token on Coinbase's Base L2, with community conversations highlighting its deep integration into the Base ecosystem and utility for AI-driven trades. Enthusiasm is rising around its potential for mass adoption, with many anticipating substantial growth and eyeing its breakout potential amidst broader market optimism and upcoming platform developments.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to high anticipation surrounding the FDA's decision on the oral VK2735 program, with the community eagerly awaiting clarity on its path to Phase 3 development. Investor attention is further amplified by recent analyst upgrades and widespread speculation of potential partnership or buyout opportunities, driven by the drug's perceived best-in-class efficacy and tolerability. While many express strong long-term conviction, there's a notable split in sentiment regarding current management's strategic communication amidst persistent short interest.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is trending due to South Korea's exceptional market performance, primarily driven by its significant exposure to semiconductor giants like Samsung and SK Hynix, which are key players in the booming memory and AI chip sector. The community is actively discussing the ETF's impressive gains and its current valuation, alongside broader market reforms in South Korea aimed at enhancing shareholder value and attracting international investment.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as discussion focuses on its pivotal role as a key partner for Microsoft's new Maia 200 AI chips and strategic acquisitions like Celestial AI, which enhance its AI interconnect and optical solutions. The community is actively debating its substantial undervaluation and long-term growth potential within the rapidly expanding AI data center infrastructure, seeing it as a critical player in the semiconductor space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.

<ul class="summary-bullets"><li>The U.S. Food and Drug Administration did not request any additional clinical studies or new patient data, as per the company.</li><li>Capricor now plans to submit the data requested by the FDA in February.</li><li>CEO Linda Marbán said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 2% on Tuesday morning after the company said that the U.S. Food and Drug Administration (FDA) has requested more data from its trials of Deramiocel.In July, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-therapeutics-stock-sparks-retail-frenzy-as-traders-hail-best-data-ahead-of-dmd-data-rollout/cLI7F7XRE0P">refused</a> to approve Capricor’s application for Deramiocel for the treatment of Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness, while also expressing the need for additional clinical data. The company said at the time that it intends to meet the FDA’s additional clinical data requirement with a late-stage study and resubmit its application.In December, the company provided the FDA with results from its late-stage HOPE-3 study in which Deramiocel delivered strong signals of benefit for muscle and heart function. However, after reviewing the data, the FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. The agency, however, did not request any additional clinical studies or new patient data, it <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on">added.</a><h2 class="st-heading-2">Fresh Timelines</h2>Capricor now plans to submit the new data requested by the FDA in February and expects that the submission will support continued review of its application and address the concerns raised by the FDA in July. &nbsp;CEO of Capricor, Linda Marbán, said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.“Our near-term priority is to address the FDA’s request and continue working collaboratively so that patients with late-stage DMD, who currently have very limited treatment options, may gain access to Deramiocel as soon as possible,” Marbán added.DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user voiced optimism for the drug getting approved in the following three to five months.<stembedurl>https://www.stocktwits.com/jamestrade07/message/642322958</stembedurl>Another user voiced hopes for the stock touching as much as $100 by end of year following Deramiocel approval.<stembedurl>https://www.stocktwits.com/haha1978/message/642314942</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 69% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think?

The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 

Equity

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average - Here's Why

Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Above 50-Day Moving Average - Time to Sell...

Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen

Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8% - What's Next?

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7.8% - Here's Why...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat...

Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen

Wall Street Zen raised Capricor Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5% - Here's What Happened

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5% - Should You Sell...

HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR

HBK Sorce Advisory LLC raised its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 33.7% in the third quarter, according to the company in its most recent disclosure with the...

HBK Sorce Advisory LLC Raises Stake in Capricor Therapeutics, Inc. $CAPR

HBK Sorce Advisory LLC lifted its stake in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 36.6% during the third quarter, according to the company in its most recent filing with...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

No change

25 bps cut

25 bps hike

Note sure, just watching

The Fed announces its rate decision this Wednesday.

Markets are pricing in a ~99% chance of no change at this week’s Fed decision, according to prediction markets. $SPY $QQQ 

FOMC on Wednesday, what do you think the Fed will decide?

Current Price	$23.62
Prev Close	$23.20
Open	$23.03
Dividend Yield	0.00%
50-Day Moving Average	$20.68
Beta	1.06
Avg. Volume	4.92M
PE Ratio	-13.13

52-Week High	$40.37
52-Week Low	$4.30
Market Capitalization	$1.26B
EPS (Annual)	-$1.15
Price to Book	12.88
Revenue Per Employee	$139,190.41
Enterprise Value/EBITDA	N/A

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CAPR News

CAPRCapricor Therapeutics Inc